Immunother Limited today announced that Eric Molstad will join the Board of Directors in the New Year and will be based in Shenzhen.
Online PR News – 30-September-2020 – SHENZHEN – Eric Molstad is a shareholder of an American bio-informatics company and is a private equity investor, and Mr. Molstad will be focused on recruiting promising talents in stem cell and bio-molecular research in Shenzhen.
Over the course of his career, Mr. Molstad has been an investor in over twenty medical start-ups that have gone on to be highly successful companies in both North America and in Asia.
Immunother Limited’s Co-Founder & Managing Director, Mr. Marcel Priest said “Eric’s deep knowledge of stem cell, and knowledge of identifying the winners of tomorrow make him a superb fit for our Board of Directors at Immunother Limited to ensure that we continue to innovate. As the world changes in unexpected and complex ways, we are thrilled to welcome Eric and the immense insight that he will bring to Immunother Limited.”
Eric Molstad commented on his appointment saying “I am honored to join Immunother Limited’s Board of Directors and have the opportunity to showcase my talents. Immunother Limited is well known for its unparalleled research, development and innovation and I look forward to contributing to Immunother Limited’s ongoing success.”
About Us - Immunother Limited
Immunother Limited Company is a privately held Shenzhen-based preclinical stage biotechnology company focused on discovering and developing novel therapies for inflammatory diseases.
Immunother Limited Company creates lasting value through pioneering research in the field of immunology which leads to new product concepts, product development, and finally to the licensing of those products and associated intellectual property.